Free tool
FAERS Monitor: Letairis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022081 or its brand name (Letairis, Ambrisentan). Reports on generic versions are filed under their own applications.
Reports
124,904
Serious
80,905
65% of reports
Hospitalization
52,784
Death reported
17,062
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea19,248
- death11,390
- headache10,875
- pneumonia7,286
- diarrhoea7,182
- fatigue6,670
- dizziness6,625
- nausea6,611
- fluid retention5,493
- malaise5,357
- cough4,658
- oedema peripheral4,223
- peripheral swelling4,080
- chest pain3,877
- nasal congestion3,820
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 67 |
| 2008 | 595 |
| 2009 | 883 |
| 2010 | 1,542 |
| 2011 | 2,831 |
| 2012 | 4,290 |
| 2013 | 9,021 |
| 2014 | 27,939 |
| 2015 | 9,463 |
| 2016 | 9,456 |
| 2017 | 9,414 |
| 2018 | 9,831 |
| 2019 | 8,079 |
| 2020 | 4,916 |
| 2021 | 4,551 |
| 2022 | 5,429 |
| 2023 | 5,506 |
| 2024 | 5,134 |
| 2025 | 3,775 |
| 2026 | 2,182 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,929,255 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fluid retentionSignal | 5,493 | 20.3 | 19.7 | 89,950 |
| nasal congestionSignal | 3,820 | 11.6 | 11.3 | 34,817 |
| oedema peripheralSignal | 4,223 | 6.0 | 5.8 | 17,109 |
| dyspnoeaSignal | 19,248 | 5.9 | 5.8 | 77,604 |
| peripheral swellingSignal | 4,080 | 4.6 | 4.4 | 11,093 |
| pneumoniaSignal | 7,286 | 3.9 | 3.8 | 15,283 |
| chest painSignal | 3,877 | 3.6 | 3.5 | 7,114 |
| headacheSignal | 10,875 | 3.0 | 2.9 | 14,242 |
| coughSignal | 4,658 | 2.8 | 2.7 | 5,481 |
| dizzinessSignal | 6,625 | 2.3 | 2.2 | 4,667 |
| deathSignal | 11,390 | 2.2 | 2.2 | 8,069 |
| malaiseSignal | 5,357 | 2.1 | 2.0 | 2,987 |
| diarrhoea | 7,182 | 1.9 | 1.8 | 3,035 |
| fatigue | 6,670 | 1.4 | 1.4 | 946 |
| nausea | 6,611 | 1.4 | 1.4 | 812 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.